In addition to these cancer types, ALKBH5 was found to be upregulated in RCC (168), HCC (169), osteosarcoma (170), esophageal epithelial cell carcinoma (171), cervical cancer (172) and oral epithelial cell carcinoma (173), suggesting that ALKBH5 is an oncogene in these cancers and that the amount of ALKBH5 upregulation is negatively associated with prognosis. Here, ALKBH5 is linked to cancer.